
    
      The primary objective of this study is to evaluate the toxicity (as measured as 100 day
      survival) after hematopoietic stem cell transplant from an unrelated donor with a novel
      preparative regimen of Fludarabine, Busulfan, Anti-Thymocyte Globulin, and Total Body
      Irradiation for pediatric patients with leukemia. The secondary objectives are to evaluate
      the relapse-free and overall survival after hematopoietic stem cell transplant as well as to
      evaluate the incidence of acute and chronic graft-versus-host disease after this preparative
      regimen.
    
  